Adoptive immunochemotherapy of a transplantable AKR leukemia (K36).
Adoptive immunotherapy of a transplantable AKR leukemia (K36) was carried out as an adjunct to cytoxan chemotherapy using normal allogeneic H-2-incompatible spleen cells as well as sensitized H-2-matched allogeneic spleen cells. A significant therapeutic effect was obtained with cytoxan and allogeneic C57BL/6 splenocytes, demonstrating the potential use of the graft-versus-host reaction. Utilizing specific adoptive immunochemotherapy, a maximum effect was found with splenocytes from allogeneic but H-2-compatible CBA/J mice immunized against an allogeneic Gross-virus-induced lymphoma (E female G2). This therapeutic effect was most likely the result of prior sensitization of donor lymphocytes to common virus-associated tumor antigens.
D000818:Animals; D000951:Antigens, Neoplasm; D003520:Cyclophosphamide / Q000627:therapeutic use; D006087:Graft vs Host Reaction; D006648:Histocompatibility; D007114:Immunization; D007167:Immunotherapy; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D014184:Transplantation, Homologous
D000951:Antigens, Neoplasm; D003520:Cyclophosphamide